Avantor executive files initial ownership report

Avantor, Inc. executive Ludovic Brellier, EVP of Bioscience & Medtech, has filed an initial Form 3 reporting his status as an insider.

Accepted by SEC EDGAR 05/05/2026 - 07:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Avantor, Inc. executive Ludovic Brellier, EVP of Bioscience & Medtech, has filed an initial Form 3 reporting his status as an insider. The provided data shows no buy, sell, or other share transactions and no derivative positions reported in this filing excerpt.

Key Terms

Form 3, EVP, Bioscience & Medtech, insider

3 terms

Form 3 regulatory

"has filed an initial Form 3 reporting his status as an insider"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

EVP, Bioscience & Medtech financial

"Ludovic Brellier, EVP of Bioscience & Medtech, has filed"

insider regulatory

"reporting his status as an insider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ludovic Brellier’s Form 3 filing for AVTR mean?

The Form 3 filing shows Ludovic Brellier is an insider at Avantor (AVTR) as EVP, Bioscience & Medtech. It is an initial ownership report, not evidence of recent stock purchases or sales in this excerpt.

Does the Avantor (AVTR) Form 3 show any insider stock purchases or sales?

In this Form 3 excerpt for Avantor (AVTR), the transaction summary lists zero buy, sell, gift, exercise, or tax-withholding transactions. It functions as a status report rather than detailing trading activity.

Who is the reporting person in Avantor’s AVTR Form 3 filing?

The reporting person is Ludovic Brellier, identified as an officer of Avantor with the title EVP, Bioscience & Medtech. The Form 3 establishes him as a company insider under SEC rules.

Does this Avantor (AVTR) Form 3 include any derivative securities?

The provided data shows an empty derivative summary for Avantor (AVTR) and zero derivative transactions. That means no options or similar instruments are reported in this specific excerpt of the Form 3.

Is Ludovic Brellier a 10% owner of Avantor (AVTR) according to this Form 3?

The Form 3 excerpt flags Ludovic Brellier as an officer but not a 10% owner of Avantor. It indicates he holds an executive role rather than reporting ownership of at least 10% of outstanding shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Brellier Ludovic

(Last) (First) (Middle)

RADNOR CORPORATE CENTER, BUILDING ONE,

SUITE 200, 100 MATSONFORD ROAD

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2026

3. Issuer Name and Ticker or Trading Symbol
Avantor, Inc. [ AVTR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Bioscience & Medtech

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Scott K. Baker, as Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)